Form 4: Supernus Exec's RSU Vesting, Tax Withholding

A Supernus Pharmaceuticals executive reported the vesting of Restricted Stock Units and subsequent share transactions for tax purposes.

Summary

• Padmanabh P. Bhatt, Sr. VP of IP and CSO of Supernus Pharmaceuticals, Inc. (SUPN), reported changes in beneficial ownership on February 24, 2026.
• The transactions involved the vesting of Restricted Stock Units (RSUs) and subsequent acquisition of common stock.
• Bhatt acquired a total of 3,125 shares of common stock upon the vesting of three separate RSU grants (1,125 shares, 750 shares, and 1,250 shares).
• A total of 1,581 shares of common stock were disposed of to satisfy tax withholding requirements related to the RSU vesting.
• The shares disposed for tax purposes were priced at $51.35 for 581 shares and $50.86 for 354 shares and 646 shares.
• Following these transactions, Bhatt's direct beneficial ownership of common stock stands at 16,444 shares.
• Remaining unvested Restricted Stock Units include 3,375 units from a grant that began vesting on February 19, 2026, and 2,500 units from a grant that began vesting on February 22, 2025.
• A grant of 750 RSUs that began vesting on February 22, 2023, is now fully vested, with 0 derivative securities remaining from that specific grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it shows an executive receiving compensation, the transactions are routine and do not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of Restricted Stock Units indicates the executive is receiving compensation, aligning their interests with shareholders.
• The acquisition of shares through RSU vesting increases the executive's direct ownership in the company.

Negatives

• A portion of the vested shares was sold to cover tax obligations, which is a common practice but reduces the executive's net increase in direct ownership.

Future Outlook

This Form 4 primarily reports past transactions and does not contain forward-looking statements or guidance about the company's future performance.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are standard compensation events for executives in the pharmaceutical industry, reflecting the long-term incentive structures common in the sector. These transactions do not typically signal a change in company fundamentals or strategic direction.

Stakeholder Impact

• Shareholders: No direct material impact on company operations or strategy; reflects standard executive compensation practices.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Future vesting installments for the remaining 3,375 Restricted Stock Units (starting February 19, 2026).
• Future vesting installments for the remaining 2,500 Restricted Stock Units (starting February 22, 2025).

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related sales) and does not provide new information that would alter the fundamental investment thesis for Supernus Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate as there are no new catalysts for a 'buy' or 'sell' decision based solely on this filing.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership, Padmanabh P. Bhatt